China Pharma Holdings, Inc. (CPHI) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CPHI Revenue Growth
Revenue Breakdown (FY 2021)
CPHI's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
CPHI Revenue Analysis (2013–2024)
As of May 8, 2026, China Pharma Holdings, Inc. (CPHI) generated trailing twelve-month (TTM) revenue of $4.1 million, reflecting significant decline in growth of -31.3% year-over-year. The most recent quarter (Q3 2025) recorded $756,217 in revenue, down 26.3% sequentially.
Looking at the longer-term picture, CPHI's 5-year compound annual growth rate (CAGR) stands at -16.1%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $32.8 million in 2013.
Revenue diversification analysis shows CPHI's business is primarily driven by DomesticPharmaceuticalsMember (100%). With over half of revenue concentrated in DomesticPharmaceuticalsMember, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CNET (-66.6% YoY), SGBX (-42.6% YoY), and SIGA (-22.1% YoY), CPHI has underperformed the peer group in terms of revenue growth. Compare CPHI vs CNET →
CPHI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CPHICurrent | $4M | -31.3% | -16.1% | -101.3% | |
 CNET | $15M | -66.6% | -23.3% | -24.3% | |
 SGBX | $5M | -42.6% | +10.8% | -195.0% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% | |
 HROW | $272M | +36.4% | +41.0% | 11.2% |
CPHI Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $4.5M | -35.4% | $-1,985,648 | -43.8% | $-4,588,866 | -101.3% |
| 2023 | $7.0M | -13.5% | $-281,085 | -4.0% | $-2,751,820 | -39.2% |
| 2022 | $8.1M | -15.9% | $-493,916 | -6.1% | $-3,548,977 | -43.8% |
| 2021 | $9.6M | -11.3% | $349K | 3.6% | $-2,860,510 | -29.7% |
| 2020 | $10.9M | -0.5% | $2.0M | 18.0% | $-2,578,293 | -23.7% |
| 2019 | $10.9M | -11.4% | $1.5M | 13.6% | $-3,389,583 | -31.0% |
| 2018 | $12.3M | -6.7% | $2.0M | 16.0% | $-3,968,357 | -32.2% |
| 2017 | $13.2M | -15.1% | $2.5M | 18.7% | $-4,496,045 | -34.0% |
| 2016 | $15.6M | -23.5% | $3.2M | 20.7% | $-4,193,326 | -26.9% |
| 2015 | $20.4M | -8.1% | $1.5M | 7.2% | $-14,195,296 | -69.8% |
See CPHI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CPHI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CPHI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCPHI — Frequently Asked Questions
Quick answers to the most common questions about buying CPHI stock.
Is CPHI's revenue growth accelerating or slowing?
CPHI revenue declined -31.3% year-over-year, contrasting with the 5-year CAGR of -16.1%. TTM revenue fell to $4M. This reverses the prior growth trend.
What is CPHI's long-term revenue growth rate?
China Pharma Holdings, Inc.'s 5-year revenue CAGR of -16.1% reflects the variable expansion pattern. Current YoY growth of -31.3% is below this long-term average.
How is CPHI's revenue distributed by segment?
CPHI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.